Cargando...
Epidermal growth factor receptor first generation tyrosine-kinase inhibitors
The epidermal growth factor receptor (EGFR) oncogene was positioned as an attractive target for drug development in non-small cell lung cancer (NSCLC). Gefitinib and erlotinib were the first two reversible inhibitors of the EGFR kinase. The discovery of EGFR kinase domain-activating mutations that s...
Guardado en:
| Publicado en: | Transl Lung Cancer Res |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
AME Publishing Company
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6894987/ https://ncbi.nlm.nih.gov/pubmed/31857948 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2019.04.20 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|